Roche’s biosimilar battle is just beginning

News

Unanimous FDA panel votes in favour of biosimilar versions of Avastin and Herceptin need not be reasons for Roche to panic just yet. Legal wrangling in the biosimilar world has meant that of the five copycat monoclonal antibodies approved in the US, only one, Pfizer’s Remicade biosimilar Inflectra, has been launched.

Still, Roche cannot delay the inevitable forever, and the eventual entry of biosimilars could put a sizeable dent in Avastin and Herceptin’s combined $14bn sales. And worryingly for the Swiss company, its current pipeline does not look capable of picking up the slack. Of the projects with EvaluatePharma sellside consensus forecasts attached, only lampalizumab and crenezumab come close in terms of peak sales (see tables below).

MAb biosimilar status in the US
Phase I Phase II Phase III Submitted Approved Marketed
Avastin 1 - 4 1 - Allergan/Amgen - -
Enbrel - 2 - - 1 - Novartis -
Herceptin 1 - 3 1 - Mylan/Biocon - -
Humira - - 7 1 - Boehringer 1 - Amgen -
Remicade 1 1 2 1 - Pfizer 2 - Samsung and Celltrion 1 - Pfizer
Source: EvaluatePharma.

Crenezumab is particularly risky as a potential replacement after its failure in phase II, as well as late-stage blow-ups with other anti-amyloid MAbs in Alzheimer’s disease. Roche still hopes that targeting earlier-stage disease will eventually lead to success, and in February started a second phase III trial in prodromal to mild Alzheimer’s.

Roche also has gantenerumab, another project targeting beta-amyloid, but with a slightly different mechanism of action. It is also in two phase III trials with results due in the next couple of years. However, Barclays analysts only give crenezumab and gantenerumab a respective 10% and 5% chance of success. With Alzheimer’s drug development notoriously tricky, Roche would be unwise to pin its hopes here.

Roche's mid-to-late stage pipeline
Global sales estimate ($m)
Project Indication Pharmacology class 2022 Peak sales
Phase III
Lampalizumab Dry age-related macular degeneration  Anti-complement factor D MAb 1,210 4,499
Emicizumab Haemophilia A  Anti-factor IXa/X bispecific MAb 1,007 -
Etrolizumab Ulcerative colitis, Crohn's disease Anti-beta 7 integrin MAb 439 1,500
Polatuzumab Vedotin Non-Hodgkin lymphoma Anti-CD79 MAb-monomethyl auristatin E conjugate 119 1,500
Crenezumab Alzheimer's disease  Anti-beta-amyloid MAb 87 4,499
Taselisib Breast cancer  Phosphatidylinositol 3-kinase inhibitor 75 1,250
Idasanutlin Acute myeloid leukaemia Murine double minute 2 inhibitor 48 -
Gantenerumab Alzheimer's disease Anti-beta-amyloid MAb 43 -
RG6168 Optic neuromyelitis Anti-IL-6 MAb 24 -
Danoprevir Hepatitis C Hepatitis C NS3/4A protease inhibitor 3 -
Phase II
RG6046 Breast cancer Selective oestrogen receptor degrader  101 -
RG7314 Autism spectrum disorders Vasopressin 1a receptor antagonist 55 -
RG7716 Wet age-related macular degeneration  Vascular endothelial growth factor A & angiopoietin 2 MAb 54 -
Lebrikizumab Eczema/dermatitis, idiopathic pulmonary fibrosis Anti-IL-13 MAb 54 1,281
Codrituzumab Hepatoma Anti-glypican 3 MAb 28 -
Olesoxime Spinal muscular atrophy Mitochondrial pore modulator 27 -
Ipatasertib Prostate, breast, stomach cancers Protein kinase B/Akt inhibitor 18 -
Source: EvaluatePharma.

Meanwhile, the consensus forecast for the dry age-related macular degeneration project lampalizumab has come down in the past year after delays to its phase III readout. Investors should finally get a look at the data in the second half of this year.

Perhaps a surer bet is the haemophilia A candidate emicizumab, which recently reported positive data from the Haven 1 and 2 trials at the International Society on Thrombosis and Haemostasis (ISTH) meeting in Berlin (Roche brings new blood to haemophilia A, June 26, 2017). 

The project is now filed with the FDA and, with breakthrough therapy designation in patients who have developed inhibitors – antibodies to factor VIII – could be approved in this population by the end of the year. But with emicizumab linked with safety concerns and rival haemophilia candidates progressing – including Alnylam’s once-monthly subcutaneous injection fitusiran and gene therapies potentially on the horizon – the haemophilia market could become crowded.

Other attempts by Roche to expand its existing products into new areas have also fallen flat, with the breast cancer drug Perjeta disappointing in the adjuvant setting.

Approvals for the Avastin and Herceptin biosimilars – Amgen’s ABP 215 and Mylan’s MYL-1401O, respectively – now look imminent, but Roche might have a bit of breathing space before their launch. Even so, it looks like it needs some fresh blood.

Project Trial ID Primary completion
Lampalizumab Spectri NCT02247531 Jul 2017
Chroma NCT02247479 Dec 2017
Gantenerumab Mild AD phase III NCT02051608 Jul 2018
Prodromal AD phase III NCT01224106 Dec 2019
Crenezumab Cread NCT02670083 Aug 2020
Cread 2 NCT03114657 Oct 2021

To contact the writer of this story email Madeleine Armstrong or Edwin Elmhirst in London at news@epvantage.com or follow @ByMadeleineA or @EdwinElmhirst on Twitter

Share This Article